Faeth Therapeutics IncFTH
Price$28.27

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Net Income -$195.5MTTM through 30 Jun 2026
Free Cash Flow -$33.9MTTM through 30 Jun 2026

Margins

Current

Returns

-113.0%ROE
-103.3%ROA

Balance Sheet Health

Current Ratio19.69x
Cash & Equivalents$26.9M

Quality Metrics

Piotroski F-Score2 / 9
Earnings-Beat Rate75.0%

Multi-Year Trend

Diluted EPS-$60.86TTM
'21'22'23'24'25
FY2025: $-16.72

Dividend

No dividend

Segment Performance

SegmentRevenueYoYOutlook
Precision Nutrition and Oncology Therapeutics
View details

Advancing clinical trials with planned readouts in endometrial and breast cancer supported by capital from the February 2026 transaction.

All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.